Winship Data News Today

Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and expands the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment this patient population.

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.

Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.

Winship Cancer Institute of Emory University has been awarded a P01 program project grant from the National Cancer Institute (NCI), nearly $11 million dollars over five years, to support research aimed at improving the effectiveness of immunotherapy for lung cancer in patients.